Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine
-
AscellaHealth Establishes International Strategic Advisory Council, Enhances Global Life Sciences Support Services Amid Regulatory and Market Complexity
-
DHCG and Altruist Biologics sign MOU to give sponsors a streamlined path to world-class biologics manufacturing in China.
-
DHCG and KunTuo sign MOU to give cell and gene therapy developers an integrated path to clinical trials in China via combined regulatory and CRO expertise.
-
DHCG and Porton Advanced sign MOU to streamline IITs in China, combining DHCG's consulting expertise with Porton's ATMP manufacturing capabilities
-
DHCG acquires CJP, a consulting firm specializing in connecting Western and Eastern therapeutic developers, expanding DHCG's Asia Pacific presence.
-
Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.
-
Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.
-
TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
-
Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology